Journal of Medical GeneticsGenetic & Genomic MedicinePeer-reviewed journal article
Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1, updates to tumour pathology and cancer incidences.
Andrew LeeiD, Nasim MavaddatiD, Alex Cunningham, Tim J. CarveriD, Lorenzo FicorellaiD, Stephanie ArcheriD, Fiona Mary WalteriD, Marc D. TischkowitziD, Jonathan RobertsiD, Juliet A. Usher‐SmithiD, Jacques SimardiD, Marjanka K. SchmidtiD, Peter DevileeiD, Vesna ZadnikiD, Hannes JürgensiD, Emmanuelle Mouret‐Fourme, Antoine De PauwiD, Matti A. RookusiD, Thea M. MooijiD, Paul D.P. PharoahiD, Douglas F. EastoniD, Antonis C. AntoniouiD
Abstract
BackgroundBOADICEA for breast cancer and the epithelial ovarian cancer (EOC) models included in the CanRisk tool (www.canrisk.org) provide future cancer risks based on rare pathogenic variants in cancer-susceptibility genes, polygenic risk scores, breast-density, questionnaire-based risk factors and family history. Here, we extend the models to include the effects of pathogenic variants in recently established breast cancer and EOC susceptibility genes, up-to-date age-specific pathology distributions and continuous risk factors. MethodsBOADICEA was extended to further incorporate the associations of pathogenic variants in BARD1, RAD51C and RAD51D with breast cancer risk. The EOC model was extended to include the association of PALB2 pathogenic variants with EOC risk. Age-specific distributions of oestrogen-receptor-negative and triple-negative breast cancer status for pathogenic variant carriers in these genes and CHEK2 and ATM were also incorporated. A novel method to include continuous risk factors was developed, exemplified by including adult-height as continuous. ResultsBARD1, RAD51C and RAD51D explain 0.31% of the breast cancer polygenic variance. When incorporated into the multifactorial model, 34-44% of these carriers would be reclassified to the near-population and 15-22% to the high-risk categories based on the UK NICE guidelines. Including height as continuous, increased the BC relative-risk variance from 0.002 to 0.010. ConclusionsThese extensions will allow for better personalised risks for BARD1, RAD51C, RAD51D and PALB2 pathogenic variant carriers and more informed choices on screening, prevention, risk factor modification or other risk-reducing options.
- Citations
- 75
- FWCI
- 9.50
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- BOADICEA model: updates to the BRCA2 breast cancer risks for ages 60 years and older
Lorenzo Ficorella, Xin Yang, … Antonis C. Antoniou·BJC ReportsPeer-reviewed·Jul 24, 2024
- A Comprehensive Epithelial Tubo-Ovarian Cancer Risk Prediction Model Incorporating Genetic and Epidemiological Risk Factors
Andrew Lee, Xin Yang, … Antonis C. Antoniou·Journal of Medical GeneticsPeer-reviewed·Nov 29, 2021
- Genomic risk prediction for breast cancer in older women
Paul A Lacaze, Andrew Bakshi, … John J. McNeil·CancersPeer-reviewed·Jul 14, 2021
- Incorporating alternative Polygenic Risk Scores into the BOADICEA breast cancer risk prediction model
Nasim Mavaddat, Lorenzo Ficorella, … Douglas F. Easton·Cancer Epidemiology Biomarkers & PreventionPeer-reviewed·Jan 13, 2023
- Meta-Analysis of Breast Cancer Risk for Individuals with PALB2 Pathogenic Variants
Thanthirige Lakshika M. Ruberu, Danielle Braun, … Swati Biswas·Genetic EpidemiologyPeer-reviewed·Apr 23, 2024
- Identification and Characterization of Rare Pathogenic Genetic Variants Associated with Breast Cancer Susceptibility in 1000 Genome and gnomAD Population
Kanishk Yadav, Abhishek Prasad·medRxiv·Aug 30, 2025